Skip to content
value.today

Candid Therapeutics, Inc.

Total raised
$206 M
1 round on record
Latest round
$206 M
Aug 2024
First round on record
Aug 2024
Today
Private
No later event on record

Funding rounds

1 counted as startup funding. Open the number of investors for the round's details.

Funding rounds of Candid Therapeutics, Inc.
MonthRaisedRaiseSizeInvestorsSoldFiling
Aug 2024$206 MNo. 1$50 to $250 million

Candid Therapeutics, Inc.: Raise no. 1, Aug 2024

Investors in this round

33 investors had bought by the notice of Sep 13, 2024: 33 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round. 4 investors are named for Candid Therapeutics, Inc. as a whole in other filings: see Investors below.

What the notice says

Amount sold
$206 M of $206 M offered
Smallest investment taken
no minimum stated
What was sold
equity
Exemption claimed
  • Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last
a year or less
Issuer's revenue
Not disclosed
Sales commissions
none
Finders' fees
none
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
The company
Corporation, incorporated in Delaware

People named in the notice

  • Arvind Kush · Executive Officer
  • Bernie Huyghe, Ph.D. · Executive Officer
  • Kenneth Song, M.D. · Executive Officer, Director
  • Timothy Lu, M.D. · Executive Officer
  • Aaron Royston, M.D. · Director
  • Jeffrey Tong, Ph.D. · Director
  • Michael Rome, M.D. · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

No one: the notice names no broker or finder paid to sell it.

Remarks in the notice

  • On the amounts: “Total Amount Sold includes amounts paid in both cash and pursuant to conversion of indebtedness.”

Signed by Kenneth Song, M.D., President and CEO. Source: SEC Form D, newest notice filed Sep 13, 2024. Read the notice at the SEC.

equitySEC

Source: SEC Form D. Each row is one private sale of securities with the running total of its newest notice. The form does not name the series or the investors; rounds are numbered in the order they were filed. A round's details show what its notice does say: accredited and other investors, the smallest investment taken, the exemption claimed, fees, the people named and the brokers paid to sell it.

How it makes money#

What its filings and its own website say, sentence by sentence, each with its source.

  • Candid Therapeutics, Inc. chose not to state its revenue in its newest notice of a funding round (Sep 2024).

    SEC Form D · Sep 2024

  • The industry group it chose in its notices: Other Health Care.

    SEC Form D · Sep 2024

That is all the official record says: Candid Therapeutics, Inc. has not published its revenue in a filing we can read, and no other official source covers it. Revenue figures come from crowdfunding filings (SEC Form C) and from annual reports once a company is listed.

Products and services#

No products or services on record: no website is on record for it in an official source (its SEC filings, Wikidata).

Investors#

4 named in official filings. Open an investor to see everything it has backed.

Investors in Candid Therapeutics, Inc.
InvestorKindAmountRoundRoleSource
Franklin Biotechnology Discovery FundFund or asset manager$3 Mheldnot statedHeld shares (fund report, Apr 2026)SEC Form N-PORT
Fidelity Advisor Health Care FundFund or asset manager$0 Mheldnot statedHolds shares (fund report, Jul 2026)SEC Form N-PORT
Fidelity Advisor Biotechnology FundFund or asset manager$0 Mheldnot statedHolds shares (fund report, Jul 2026)SEC Form N-PORT
VIP Health Care PortfolioFund or asset manager$0 Mheldnot statedHolds shares (fund report, Jun 2026)SEC Form N-PORT

Source: SEC Form 3 statements, SEC Form N-PORT fund reports, Wikidata, value.today research. Names come from filings that do name holders: the preferred stock each holder had when the company registered its shares (Form 3), private shares in US mutual funds' portfolio reports (N-PORT), and Wikidata. None ties a name to one funding round, so this list is per company, and it is not complete: the 1 round above had up to 33 investors.

Executives and directors

As the company named them in its notices. Directors of a funded startup are often partners of its investors.

People named by Candid Therapeutics, Inc.
NameRoleNamed in
Arvind KushExecutive officerSep 2024
Bernie Huyghe, Ph.D.Executive officerSep 2024
Kenneth Song, M.D.Executive officerSep 2024
Timothy Lu, M.D.Executive officerSep 2024
Aaron Royston, M.D.DirectorSep 2024
Jeffrey Tong, Ph.D.DirectorSep 2024
Kenneth Song, M.D.DirectorSep 2024
Michael Rome, M.D.DirectorSep 2024